Inside Nexalin: Drug-Free Neuro Tech, Clinical Milestones, and What’s Next!

Mark White, CEO of Nexalin Technology (Nasdaq: NXL), joins us to discuss how Nexalin aims to simplify and make mental health care more accessible with its at-home “Halo” headset and a digital, physician-monitored model. We cover the latest peer-reviewed study results referenced by the company, the plan for U.S. and international pathways, and what investors should watch next.🎯 What you’ll learn• Nexalin’s vision for easy, drug-free, non-invasive support delivered at home• How the “Halo” headset fits into a virtual care workflow (physician-monitored)• Key takeaways from the company-referenced, peer-reviewed Alzheimer’s study• Commercial model: device + subscription (“razor/razor-blade” economics)• Near-term focus areas: mood/anxiety/sleep, TBI/PTSD, and early dementia• How management thinks about FDA strategy and global expansion🧠 Study reference (as discussed)• Nexalin references a peer-reviewed publication reporting statistically significant cognitive improvements and fMRI-observed connectivity changes in a mild Alzheimer’s cohort using a 40-Hz, 15 mA protocol, with no adverse events reported during the treatment period. 💼 Business model• Clinical setting: device placement with physicians; recurring revenue via single-use disposables/treatments• At-home: headset prescribed/ordered by a physician; subscription to access and remote monitoring via app/cloud• Goal: scale through a digital ecosystem that integrates diagnosis, treatment access, and physician oversight🔎 For investors• Thesis: simplified access, physician-monitored use at home, and recurring revenue economics could unlock a capital-efficient growth path if regulatory and clinical milestones are achieved.• Watchlist catalysts: additional study readouts, regulatory interactions/decisions, progress on U.S. pathway, international indication expansions, commercial pilots/rollouts, and updates on subscription adoption and reimbursement discussions.🔔 Drop your questions for Mark in the comments for future Q&A!Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Nexalin is a client of RedChip. To learn more about NXL and to read our full disclosure, visit: NXLinfo.com.#Nexalin #NXL #MedTech #DigitalHealth #BrainHealth #Investing #Neurotechnology #Alzheimers #MentalHealth #AtHomeCare